Previous Close | 0.1979 |
Open | 0.1550 |
Bid | 0.0000 x 900 |
Ask | 0.0000 x 3000 |
Day's Range | 0.1550 - 0.1550 |
52 Week Range | 0.1100 - 0.4000 |
Volume | |
Avg. Volume | 3,103 |
Market Cap | 17.557M |
Beta (5Y Monthly) | 1.19 |
PE Ratio (TTM) | 0.01 |
EPS (TTM) | 10.9900 |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
EOM Pharmaceutical Holdings, Inc. (OTC: IMUC) ("EOM") today provides an update on its clinical program for its lead drug candidate EOM613. EOM613 is a peptide-nucleic acid-based broad spectrum immune regulating agent that acts on both key pro-inflammatory and anti-inflammatory cytokines with potential therapeutic utility in treating a variety of acute and chronic inflammatory conditions.